What's Happening With Novo Nordisk Stock Today?

Novo Nordisk A/S (NYSE:NVO) shares are moving higher on Thursday. Hims & Hers Health Inc (NYSE:HIMS) announced it will begin offering several of Novo’s FDA‑approved GLP‑1 medications, including the newly launched Wegovy pill. Novo Nordisk stock is building positive momentum. Why are NVO shares climbing? Hims & Hers Expands Access To Novo Nordisk GLP‑1 Treatments Hims & Hers said it is now making a wide range of Novo Nordisk's GLP‑1 drugs available to eligible customers, including the Wegovy pill, currently the only FDA‑approved oral GLP‑1 treatment for weight loss. Eligible users can now be prescribed Novo Nordisk treatments that have been shown to help patients lose up to 20% of their body weight, depending on an independent provider's clinical assessment. Available options include Wegovy injections in multiple strengths — 0.25 mg, 0.5 mg, 1 mg, 1.7 mg and 2.4 mg — as well as oral doses of 1.5 mg, 4 mg, 9 mg and 25 mg. A 7.2 mg injectable dose is expected to be added soon. Pricing starts at $149 per month. Ozempic injection pens, which are approved for Type 2 diabetes, will also be offered to eligible patients based on clinical judgment, though the drug is not approved for weight loss. Hims & Hers CEO Andrew Dudum said the move represents "an important next step toward building a better model of healthcare that works for everyday people," adding that collaboration between healthcare innovators helps ensure access keeps pace with medical advances. NVO Stock Momentum Leans Bullish Novo Nordisk is trading 2.5% below its 20-day SMA and 23.7% below its 100-day SMA, keeping the intermediate trend pointed down even as the stock tries to stabilize. Shares are down 48.54% over the past 12 months and are positioned much closer to their 52-week low than their high. RSI is at 30.46, which is neutral but sitting right on the doorstep of oversold conditions after the RSI dipped below 30 on 2026-02-23. Meanwhile, MACD is at -2.4892 versus a signal line of -2.8457, a bullish configuration that suggests downside momentum is easing even though the trend is still damaged. RSI in the 30-50 range with bullish MACD indicates momentum leaning bullish. Key Resistance: $39.50 Key Support: $36.00 Analyst Consensus & Recent Actions: The stock carries a Buy Rating with an average price target of $97.75. Recent analyst moves include: Goldman Sachs: Downgraded to Neutral (Lowers Target to $41.00) (Mar. 2) JP Morgan: Downgraded to Neutral (Feb. 24) CICC: Initiated with Outperform (Target $73.50) (Jan. 9) Benzinga Edge Rankings: The Benzinga Edge scorecard for Novo-Nordisk highlights its strengths and weaknesses compared to the broader market. Momentum: Bearish (Score: 3.96) — The stock is lagging badly versus the broader market, which fits with its deeply negative 12-month trend. Quality: Bullish (Score: 96.37) — The score implies strong underlying business quality, even though the chart is still trying to repair. Value: Neutral (Score: 48.04) — Valuation looks closer to the middle of the pack, suggesting the market isn't pricing it as either a clear bargain or a clear premium. Growth: Bullish (Score: 93.17) — Growth characteristics remain a key part of the story, which can matter if sentiment turns back toward fundamentals. The Verdict: Novo-Nordisk’s Benzinga Edge signal reveals a fundamentals-strong but price-weak setup, with elite Growth and Quality scores contrasted by very bearish Momentum. For longer-term investors, that often frames the stock as a "watch for trend reversal" candidate — especially if it can hold $36.00 support and start reclaiming key moving averages. NVO Price Action: Novo Nordisk shares were up 1.24% at $36.78 at the time of publication on Thursday. The stock is trading near its 52-week low of $35.85, according to Benzinga Pro. Image: Piotr Swat/Shutterstock